Followers | 241 |
Posts | 12150 |
Boards Moderated | 3 |
Alias Born | 04/05/2009 |
Monday, December 15, 2014 10:51:55 PM
FORT WORTH — Sundie Ellis, 40, is busy again, working full time for the first time in years.
"Before Lemtrada, I worked about three or four hours a day," she said. "Now I work a full day — plus I help out around the house, which is not something I could do."
Multiple sclerosis triggered serious nerve pain, exhausting fatigue, and mental confusion in Ellis for 11 years. She took 15 medications daily just to function.
In desperation, she traveled to Germany in April to receive infusions of a drug called Lemtrada for five consecutive days. The once-a-year therapy has the potential to help alleviate MS symptoms.
In some cases, lost function has been restored.
Lemtrada was not approved by the Food and Drug Administration for use in the United States when Ellis made her transatlantic journey.
It wasn't the potential for serious side effects — including kidney failure and thyroid cancer — that led to the FDA decision. Rather, Lemtrada had not been tested in double-blind, placebo-controlled studies, like most other drugs.
Lemtrada did have years of testing, however, and had been approved for use in 40 other countries. Many MS patients were willing to travel overseas and pay for the drug out of pocket, at a cost of more than $100,000.
Ellis said not long after the therapy, she stopped needing most of the medications she had been taking.
"And any time you get rid of one medicine, you get rid of the side effects that come with it," she said. "So it was kind of lifting of symptoms, and the day was better."
In November, the FDA approved Lemtrada for use in the U.S.
"Its biggest effect is to give people hope," Ellis said.
Now, she says she has hope and energy to live life again. When she needs another infusion next year, she'll only have to travel down the street — not to Germany — to get it.
http://www.wfaa.com/story/news/health/2014/12/15/lemtrada-approved-for-treatment-of-multiple-sclerosis-in-us/20451859/
[MEI brought this story to my attention]
"Someone said it takes 30 years to be an instant success" - Gabriel Barbier-Mueller, CEO of Harwood International
Recent SNY News
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old • GlobeNewswire Inc. • 09/20/2024 11:45:00 AM
- Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA • PR Newswire (US) • 09/16/2024 12:00:00 PM
- Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) • GlobeNewswire Inc. • 09/13/2024 04:15:28 PM
- Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares • Business Wire • 09/12/2024 06:37:00 AM
- Sanofi, RadioMedix, and Orano Med Announce Licensing Agreement on Next-Generation Radioligand Medicine for Rare Cancers • Business Wire • 09/12/2024 06:37:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 08/13/2024 01:06:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 10:30:03 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/13/2024 10:05:25 AM
- Le vaccin FluzoneMD Haute Dose Quadrivalent demeure le vaccin préférentiellement recommandé pour protéger les adultes de 65 ans et plus contre la grippe • PR Newswire (Canada) • 07/26/2024 04:08:00 PM
- Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza • PR Newswire (Canada) • 07/26/2024 03:17:00 PM
- Earnings Updates: Ford Shares Fall 13% on EPS Miss, Stellantis Down 6%, Viking Therapeutics Up 20%, Unilever Up 5% • IH Market News • 07/25/2024 10:19:48 AM
- Sanofi ships U.S. influenza vaccines for the 2024/25 season • PR Newswire (US) • 07/10/2024 08:10:00 PM
- BP Slashes Profit Forecast by $700 Million; Morgan Stanley Predicts S&P 500 10% Drop, and More News • IH Market News • 07/09/2024 10:54:32 AM
- Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine • GlobeNewswire Inc. • 06/26/2024 09:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/11/2024 05:54:55 PM
- I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer • PR Newswire (US) • 06/06/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 05/31/2024 08:30:55 PM
- Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD • GlobeNewswire Inc. • 05/31/2024 05:05:00 AM
- Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation • GlobeNewswire Inc. • 05/31/2024 05:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/30/2024 08:30:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 04:04:28 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/28/2024 02:34:56 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- CalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More News • IH Market News • 05/21/2024 11:18:35 AM
- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) • GlobeNewswire Inc. • 05/13/2024 05:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM